Cited by 796Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.

New insights into the pharmacodynamic and pharmacokinetic properties of statins

Corsini, Alberto, Bellosta, Stefano, Baetta, Roberta, Fumagalli, Remo, Paoletti, Rodolfo, Bernini, Franco·1999·Pharmacology & Therapeutics

DOI 10.1016/s0163-7258(99)00045-5

Open this paper in CoChat — free account

Abstract

The beneficial effects of statins are assumed to result from their ability to reduce cholesterol biosynthesis. However, because mevalonic acid is the precursor not only of cholesterol, but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase may result in pleiotropic effects. It has been shown that several statins decrease smooth muscle cell migration and proliferation and that sera from fluvastatin-treated patients interfere with its proliferation. Cholesterol accumulation in macrophages can be inhibited by different statins, while both fluvastatin and simvastatin inhibit secretion of metalloproteinases by human monocyte-derived macrophages. The antiatherosclerotic effects of statins may be achieved by modifying hypercholesterolemia and the arterial wall environment as well. Although statins rarely have severe adverse effects, interactions with other drugs deserve attention. Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme. Indeed, pharmacokinetic interactions (e.g., increased bioavailability), myositis, and rhabdomyolysis have been reported following concurrent use of simvastatin or lovastatin and cyclosporine A, mibefradil, or nefazodone. In contrast, fluvastatin (mainly metabolized by cytochrome P450-2C9) and pravastatin (eliminated by other metabolic routes) are less subject to this interaction. Nevertheless, a 5- to 23-fold increase in pravastatin bioavailability has been reported in the presence of cyclosporine A. In summary, statins may have direct effects on the arterial wall, which may contribute to their antiatherosclerotic actions. Furthermore, some statins may have lower adverse drug interaction potential than others, which is an important determinant of safety during long-term therapy.

Integrity signals

Registry

Crossref · 10.1016/s0163-7258(99)00045-5

Cites

187 of 187 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 9,216
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Coronary Plaque Disruption
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 2,018

Show all 186 references

Research works printed but not linked: 8

Fischer, 1999, The HMG-CoA reductase inhibitor fluvastatin, Drug Metab Dispos, 27, 410
Henwood, 1995, Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia, Drugs, 31, 9
Hoffman, 1992, The interaction of lovastatin and warfarin, Conn Med, 56, 107
Mai, 1997, Clinical pharmacokinetics of a new HMG-CoA reductase inhibitor in renal transplant patients treated with cyclosporin A (CSA), Eur J Clin Pharmacol, 52, A137
Raiteri, 1997, Pharmacological control of the mevalonate pathway, J Pharmacol Exp Ther, 281, 1144
1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, Lancet, 344, 1383
Smith, 1991, HMG-CoA reductase inhibitor-induced myopathy in the rat, J Pharmacol Exp Ther, 257, 1225
Soma, 1995, In vitro and in vivo enhanced anti-tumor activity of carmustine (BCNU) by simvastatin, a hypocholesterolemic drug, Cancer Res, 55, 597

Sorted by citations

Items 301–400 of 794

Fluvastatin Inhibits Hypoxic Proliferation and p38 MAPK Activity in Pulmonary Artery Fibroblasts
Carlin, C. M., Peacock, A. J., & Welsh, D. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0012oc · Cited by 35
Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women
Thompson, K., Keech, F., McLernon, D. J., Vinod, K., May, R. J., Simpson, W. G., Rogers, M. J., & Reid, D. M. (2010) · Bone · doi:10.1016/j.bone.2010.10.177 · Cited by 34
Pharmacology of Nutraceuticals with Lipid Lowering Properties
Poli, A., & Visioli, F. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00311-x · Cited by 34
A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis
Liu, Y., Liu, P., Song, Y., Li, S., Shi, Y., Quan, K., Guo, Y., Li, P., An, Q., & Zhu, W. P. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00867-8 · Cited by 34
Systematic Development of Self-Emulsifying Drug Delivery Systems of Atorvastatin with Improved Bioavailability Potential
Khan, F. (2012) · Scientia Pharmaceutica · doi:10.3797/scipharm.1201-06 · Cited by 34
Memory restorative role of statins in experimental dementia: an evidence of their cholesterol dependent and independent actions
Dalla, Y., Singh, N., Jaggi, A. S., & Singh, D. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70339-x · Cited by 34
Apoptosis in atherosclerosis: pathological and pharmacological implications
Guevara, J., Chen, K.-H., & Chan, L. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0840 · Cited by 34
Synergistic antimyeloma effects of zoledronate and simvastatin
Schmidmaier, R., Şimşek, M., Baumann, P., Emmerich, B., & Meinhardt, G. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000215058.85813.02 · Cited by 35
The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs
Nogueira, J. M., & Weir, M. R. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04131206 · Cited by 34
Inhibition of Interferon-beta Responses in Multiple Sclerosis Immune Cells Associated With High-Dose Statins
Feng, X., Han, D. S. C., Kilaru, B. K., Franek, B. S., Niewold, T. B., & Reder, A. T. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.465 · Cited by 33
Tissue-Engineered Human Myobundle System as a Platform for Evaluation of Skeletal Muscle Injury Biomarkers
Khodabukus, A., Kaza, A., Wang, J., Prabhu, N. K., Goldstein, R., Vaidya, V. S., & Bursac, N. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa049 · Cited by 34
AN OVERVIEW OF STATINS AS HYPOLIPIDEMIC DRUGS
Rao, K. S., Prasad, T., Mohanta, G. P., & Manna, P. K. (2011) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2011.030303 · Cited by 33
Effect of 3-hydroxy-3-methylglutarylcoenzyme A Reductase Inhibitors (Statins) on Tissue Paraoxonase 1 and Plasma Platelet Activating Factor Acetylhydrolase Activities
Bełtowski, J., Wójcicka, G., & Jamroz, A. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200401000-00018 · Cited by 33
Lacidipine [correction of Lalsoacidipine] modulates the secretion of matrix metalloproteinase-9 by human macrophages.
Bellosta, S., Canavesi, M., Favari, E., Cominacini, L., Gaviraghi, G., Fumagalli, R., Paoletti, R., & Bernini, F. (2001) · PubMed · Cited by 33
Self-citation
High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application
Polagani, S. R., Pilli, N. R., & Gandu, V. (2012) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2012.01.001 · Cited by 32
Influence of the Use of Statin on the Stability of Erythrocyte Membranes in Multiple Sclerosis
de Freitas, M. V., de Oliveira, M. R., dos Santos, D. F., Netto, R. D. C. M., Fenelon, S. B., & Penha‐Silva, N. (2010) · The Journal of Membrane Biology · doi:10.1007/s00232-010-9232-y · Cited by 32
Muscle Symptoms Associated with Statins: A Series of Twenty Patients
Soininen, K., Niemi, M., Kilkki, E., Strandberg, T. E., & Kivist, K. T. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_193.x · Cited by 32
Biological consequences of statins in Candida species and possible implications for human health
Wikhe, K., Westermeyer, C., & Macreadie, I. G. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351529 · Cited by 31
Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using ‘In silico Pharmacology’
Chakraborty, C., George, C., Chen, L., & Zhu, H. (2014) · Current Protein and Peptide Science · doi:10.2174/1389203715666140724090153 · Cited by 32
Potential statin drug interactions in elderly patients: a review
Damiani, I., Corsini, A., & Bellosta, S. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1822324 · Cited by 31
Self-citation
Simvastatin induces cell death in a mouse cerebellar slice culture (CSC) model of developmental myelination
Xiang, Z., & Reeves, S. A. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.09.010 · Cited by 31
Critical review of statins: A bio-analytical perspective for therapeutic drug monitoring
Patel, M., & Kothari, C. S. (2016) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2016.10.011 · Cited by 31
Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal
Askarizadeh, A., Butler, A. E., Badiee, A., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27121 · Cited by 31
Novel Statins: Pharmacological and Clinical Results
Bolego, C., Poli, A., Cignarella, A., Catapano, A. L., & Paoletti, R. (2002) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1020656607497 · Cited by 31
Self-citation
How Well Tolerated Are Lipid-Lowering Drugs?
Tomlinson, B., Chan, P., & Lan, W. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00003 · Cited by 31
Simvastatin inhibits cytokine‐stimulated Cyr61 expression in osteoblastic cells: A therapeutic benefit for arthritis
Kok, S., Hou, K., Hong, C., Wang, J., Liang, P., Chang, C., Hsiao, M., Yang, H., Lai, E. H., & Lin, S. (2011) · Arthritis & Rheumatism · doi:10.1002/art.27433 · Cited by 30
Bone critical defect repair with poloxamine–cyclodextrin supramolecular gels
del Rosario, C., Rodríguez‐Évora, M., Reyes, R., Simões, S. M. N., Concheiro, Á., Évora, C., Alvarez‐Lorenzo, C., & Delgado, A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.09.003 · Cited by 30
Examination of the FDA Warning for Statins and Cognitive Dysfunction
Sahebzamani, F. M. (2014) · Journal of Pharmacovigilance · doi:10.4172/2329-6887.1000141 · Cited by 30
Atorvastatin calcium inclusion complexation with polysaccharide arabinogalactan and saponin disodium glycyrrhizate for increasing of solubility and bioavailability
Kong, R., Zhu, X., Meteleva, E. S., Polyakov, N. E., Khvostov, M. V., Baev, D. S., Толстикова, Т. Г., Dushkin, A. V., & Su, W. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0565-x · Cited by 30
Antidepressant and Statin Interactions: A Review and Case Report of Simvastatin and Nefazodone-Induced Rhabdomyolysis and Transaminitis
Karnik, N. S., & Maldonado, J. R. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.6.565 · Cited by 30
Modulatory Effects of Atorvastatin on Endothelial Cell–Derived Chemokines, Cytokines, and Angiogenic Factors
Zineh, I., Luo, X., Welder, G. J., DeBella, A. E., Wessel, T. R., Arant, C. B., Schofield, R. S., & Chegini, N. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.333 · Cited by 30
Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins
Banfi, C., Baetta, R., Gianazza, E., & Tremoli, E. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.001 · Cited by 31
Self-citation
Atorvastatin
Wierzbicki, A. S. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.5.819 · Cited by 30
Lipid-modified proteins as biomarkers for cardiovascular disease: a review
Ferri, N., Paoletti, R., & Corsini, A. (2005) · Biomarkers · doi:10.1080/13547500500216660 · Cited by 30
Self-citation
Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol
Corsini, A., Windier, E. T. E., & Farnier, M. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32831215db · Cited by 30
Self-citation
Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism
Thompson, J. M., Álvarez, A., Singha, M. K., Pavesic, M. W., Nguyen, Q., Nelson, L. J., Fruman, D. A., & Razorenova, O. V. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1076 · Cited by 30
Pitavastatin slows tumor progression and alters urine‐derived volatile organic compounds through the mevalonate pathway
Wang, L., Wang, Y., Chen, A. B., Teli, M., Kondo, R., Jalali, A., Fan, Y., Liu, S., Zhao, X., Siegel, A. P., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201901388r · Cited by 29
Treatment of dyslipidemia in kidney transplantation
Ponticelli, C. E., Arnaboldi, L., Moroni, G. L., & Corsini, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1732921 · Cited by 29
Self-citation
Pharmacotherapy of hypercholesterolaemia: statins in clinical practice
Moghadasian, M. H., Mancini, G. J., & Frohlich, J. J. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.683 · Cited by 29
Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile
Kumar, N., Chaurasia, S., Patel, R. R., Khan, G., Kumar, V., & Mishra, B. (2015) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2015.1108983 · Cited by 29
Statins and their interactions with other lipid-modifying medications: safety issues in the elderly
Ho, C. K. M., & Walker, S. W. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611428486 · Cited by 29
Evolution and Stabilization of Vulnerable Atherosclerotic Plaques
Libby, P., & Aikawa, M. (2001) · Japanese Circulation Journal-english Edition · doi:10.1253/jcj.65.473 · Cited by 29
Rosuvastatin improves vascular function of arteriovenous fistula in a diabetic rat model
Roan, J., Fang, S., Chang, S.-W., Hsu, C., Huang, C.-C., Chiou, M.-H., Tsai, Y., & Lam, C.-F. (2012) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2012.03.243 · Cited by 28
Alzheimer Disease—No Target for Statin Treatment. A Mini Review
Hoyer, S., & Riederer, P. F. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9168-x · Cited by 28
PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-ε-caprolactone nanoparticles
Ahmed, I. S., Hosary, R. E., Shalaby, S. H., Abd‐Rabo, M. M., ElKhateeb, D. G., & Nour, S. A. E.-K. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.03.045 · Cited by 28
Drug–drug interaction with statins
Corsini, A., & Bellosta, S. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.1.105 · Cited by 28
Self-citation
Steady‐state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol® XL
Barilla, D., Prasad, P., Hubert, M., & Gumbhir‐Shah, K. (2004) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.378 · Cited by 28
NK‐104, a 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells
Takemoto, M., Kitahara, M., Yokote, K., Asaumi, S., Take, A., Saitō, Y., & Mori, S. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704046 · Cited by 28
Bivariate and multivariate analyses of the correlations between stability of the erythrocyte membrane, serum lipids and hematological variables
Neto, M. B., E.B. de Avelar, Jr., Arantes, T. S., Jordão, I., Huss, J. C. D. C., de Souza, T. M. T., Penha, V. A. D. S., da Silva, S. C., de Souza, P. C. A., Tavares, M., et al. (2013) · Biorheology · doi:10.3233/bir-130641 · Cited by 27
Combination of calcium sulfate and simvastatin-controlled release microspheres enhances bone repair in critical-sized rat calvarial bone defects
Ho, M., Fu, Y., Wang, Y., Chen, C., Wang, C., & Wang, G. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s88134 · Cited by 27
Antitumor effects of bisphosphonates
Berenson, J. R. (2011) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e328349dc17 · Cited by 28
The Study of the Influence of Formulation and Process Variables on the Functional Attributes of Simvastatin–Phospholipid Complex
Saoji, S. D., Belgamwar, V. S., Dharashivkar, S., Rode, A. A., Mack, C., & Dave, V. S. (2016) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-016-9256-7 · Cited by 27
Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy
Muñoz, A., Pollarsky, F. D., Marino, M., Cartier, M., Vázquez, H., Salgado, P., & Romero, G. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i28.4639 · Cited by 27
The Potential Therapeutic Application of Simvastatin for Brain Complications and Mechanisms of Action
Vuu, Y. M., Shahib, A. K., & Rastegar, M. (2023) · Pharmaceuticals · doi:10.3390/ph16070914 · Cited by 33
Statins demonstrate a broad anti-cytomegalovirus activity in vitro in ganciclovir-susceptible and resistant strains
Ponroy, N., Taveira, A., Mueller, N. J., & Millard, A. (2014) · Journal of Medical Virology · doi:10.1002/jmv.23998 · Cited by 30
Lipid and Non-lipid Effects of Statins
Paoletti, R., Bolego, C., & Cignarella, A. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-27661-0_13 · Cited by 27
Self-citation
Hypolipidemic therapy for the metabolic syndrome
Cignarella, A., Bellosta, S., Corsini, A., & Bolego, C. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.03.012 · Cited by 27
Self-citation
Lipid-Lowering Effects of Ethyl 2-Phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in Rodents
Holub, J. M., O'Toole-Colin, K., Getzel, A., Argenti, A., Evans, M. A., Smith, D. C., Dalglish, G. A., Rifat, S., Wilson, D. L., Taylor, B. M., et al. (2004) · Molecules · doi:10.3390/90300134 · Cited by 27
Combination therapy in the management of complex dyslipidemias
Davidson, M. H., & Toth, P. P. (2004) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000137221.16160.b9 · Cited by 27
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
Belinchón, F. J. Z., Moeller, R. A., Laßwitz, L., van Ham, M., Becker, M., Brogden, G., Rosendal, E., Bi, W., Carriquí-Madroñal, B., Islam, K., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103469 · Cited by 25
Intratracheal instillation of pravastatin for the treatment of murine allergic asthma: a lung-targeted approach to deliver statins
Zeki, A. A., Bratt, J. M., Chang, K. Y., Franzi, L. M., Ott, S. P., Silveria, M., Fiehn, O., Last, J. A., & Kenyon, N. J. (2015) · Physiological Reports · doi:10.14814/phy2.12352 · Cited by 26
The matrix metalloproteinases as pharmacological target in osteoarthritis: Statins may be of therapeutic benefit
Wu, Y., Hu, Y. Y., Yang, R. F., Wang, Z., & Wei, Y. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2007.01.042 · Cited by 26
Photostability of pitavastatin—A novel HMG-CoA reductase inhibitor
Grobelny, P. J., Viola, G., Vedaldi, D., Dall’Acqua, F., Gliszczyńska‐Świgło, A., & Mielcarek, J. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.10.004 · Cited by 26
Simple, sensitive and rapid LC–MS/MS method for the quantitation of cerivastatin in human plasma — application to pharmacokinetic studies
Ramakrishna, N. V. S., Koteshwara, M., Vishwottam, K. N., Puran, S., Manoj, S., & Santosh, M. (2004) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2004.06.022 · Cited by 26
Correction: Targeting Iron Acquisition Blocks Infection with the Fungal Pathogens Aspergillus fumigatus and Fusarium oxysporum
Leal, S. M., Roy, S., Vareechon, C., Carrion, S. D. J., Clark, H., López‐Berges, M. S., Pietro, A. D., Schrettl, M., Beckmann, N., Redl, B., et al. (2013) · PLoS Pathogens · doi:10.1371/annotation/4f388450-90fe-4c65-9b9b-71a2b7935ac0 · Cited by 27
Endothelial Relaxation Mechanisms and Oxidative Stress Are Restored by Atorvastatin Therapy in Ovariectomized Rats
Caliman, I. F., Lamas, A. Z., Dalpiaz, P. L. M., Medeiros, A. R. S., Abreu, G. R., de Figueiredo, S. G., Gusmão, L. N., de Andrade, T. U., & Bissoli, N. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080892 · Cited by 25
Protein geranylgeranylation controls collagenase expression in osteoarthritic cartilage
Sverdrup, F. M., Yates, M. P., Vickery, L. E., Klover, J. A., Song, L. R.-H., Anglin, C. P., & Misko, T. P. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.03.015 · Cited by 23
Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53
CHAN, K., Wang, C. C., Ho, H., Chen, H., & Huang, C. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.08.005 · Cited by 25
Potential of novel drug delivery strategies for the treatment of hyperlipidemia
Mathur, M., & Devi, V. K. (2016) · Journal of drug targeting · doi:10.3109/1061186x.2016.1172586 · Cited by 25
Distribution of lovastatin to bone and its effect on bone turnover in rats
Jadhav, S. B., Murthy, P. S. N., Singh, M. M., & Jain, G. K. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.11.0005 · Cited by 25
Pitavastatin Effect on ATP Binding Cassette A1-Mediated Lipid Efflux from Macrophages: Evidence for Liver X Receptor (LXR)-Dependent and LXR-Independent Mechanisms of Activation by cAMP
Zanotti, I., Potì, F., Favari, E., Steffensen, K. R., Gustafsson, J.-Α., & Bernini, F. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093930 · Cited by 25
Self-citation
Fluvastatin
Corsini, A., Jacobson, T. A., & Ballantyne, C. M. (2004) · Drugs · doi:10.2165/00003495-200464120-00004 · Cited by 26
Self-citation
The potential of Atorvastatin for chronic lung diseases therapy
Tulbah, A. S. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.08.025 · Cited by 23
Effect of Clopidogrel on the Steady‐State Pharmacokinetics of Fluvastatin
Ayalasomayajula, S. P., Vaidyanathan, S., Kemp, C. N., Prasad, P., Balch, A. H., & Dole, W. P. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006299138 · Cited by 24
Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: Synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator
Lapchak, P. A., & Han, M. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.035 · Cited by 24
Ligand based analysis on HMG-CoA reductase inhibitors
Moorthy, N. S. H. N., Cerqueira, N. M. F. S. A., Ramos, M. J., & Fernandes, P. A. (2014) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2014.11.009 · Cited by 25
Statins and the Joint: Multiple Targets for a Global Protection?
Lazzerini, P. E., Capecchi, P. L., Selvi, E., Lorenzini, S., Bisogno, S., Baldari, C. T., Galeazzi, M., & Pasini, F. L. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.06.010 · Cited by 24
Atorvastatin Calcium Inhibits PDGF-ββ-Induced Proliferation and Migration of VSMCs Through the G0/G1 Cell Cycle Arrest and Suppression of Activated PDGFRβ-PI3K-Akt Signaling Cascade
Chen, S., Dong, S., Zhao, L., Guo, X., Zhang, N., Yu, B., & Sun, Y. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484648 · Cited by 24
Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: A review
Lughetti, L., Predieri, B., Balli, F., & Calandra, S. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03347453 · Cited by 24
The potential therapeutic role of statins in central nervous system autoimmune disorders
ve, O. S. A. U., Youssef, S., Dunn, S. E., Slavin, A., Steinman, L., & Zamvil, S. S. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3146-0 · Cited by 24
A Comparison of Six Statins on the Development of Intimal Hyperplasia in a Human Vein Culture Model
Corpataux, J.-M., Naik, J., Porter, K. E., & London, N. J. M. (2004) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2004.11.003 · Cited by 24
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits
Lapchak, P. A., & Han, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.09.064 · Cited by 24
Comparison of the Efficacy and Tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial
OLSSON, A. G. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80029-1 · Cited by 24
Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?
Faggiotto, A., & Paoletti, R. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0091-3 · Cited by 23
Self-citation
Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes
Galgóczy, L., Lukács, G., Nyilasi, I., Papp, T., & Vágvölgyi, C. (2010) · Acta Biologica Hungarica · doi:10.1556/abiol.61.2010.3.11 · Cited by 23
Atorvastatin Inhibits the HIF1α-PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells
Nakashima, Y., Miyagi‐Shiohira, C., Noguchi, H., & Ōmasa, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.005 · Cited by 24
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia
Ma, Y.-B., Chan, P., Zhang, Y., Tomlinson, B., & Liu, Z. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594776 · Cited by 23
Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making
Reig-López, J., García‐Arieta, A., Sanjuan, V. M., & Merino‐Sanjuán, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050709 · Cited by 24
Use of an indirect effect model to describe the LDL cholesterol‐lowering effect by statins in hypercholesterolaemic patients
Faltaos, D. W., Urien, S., Carreau, V., Chauvenet, M., Hulot, J., Giral, P., Bruckert, É., & Lechat, P. P. (2006) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00404.x · Cited by 23
Suboptimal choices and dosing of statins at start of therapy
Mantel-Teeuwisse, A. K., Klungel, O. H., Schalekamp, T., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02367.x · Cited by 23
Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells
Lazzerini, P. E., Capperucci, C., Spreafico, A., Capecchi, P. L., Niccolini, S., Ferrata, P., Frediani, B., Galeazzi, M., & Pasini, F. L. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.07.007 · Cited by 23
From Finland to Fatland
Afzali, B., Haydar, A. A., Vinen, K., & Goldsmith, D. J. A. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000133252.07149.05 · Cited by 23
Are Statins Applicable for the Prevention and Treatment of Zygomycosis?
Galgóczy, L., Nyilasi, I., Papp, T., & Vágvölgyi, C. (2009) · Clinical Infectious Diseases · doi:10.1086/600825 · Cited by 22
Sustained release of simvastatin from hollow carbonated hydroxyapatite microspheres prepared by aspartic acid and sodium dodecyl sulfate
Wang, K., Wang, Y., Zhao, X., Li, Y., Yang, T., Zhang, X., & Wu, X. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.02.066 · Cited by 22
Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors
Roy, S., Weinstock, J. L., Ishino, A. S., Benites, J., Pop, S. R., Perez, C., Gumbs, E. A., Rosenbaum, J. A., Roccato, M. K., Shah, H., et al. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3066w · Cited by 23
Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC‐MS/MS and its application to a human pharmacokinetic study
Pilli, N. R., Mullangi, R., Inamadugu, J. K., Nallapati, I. K., & Rao, J. V. L. N. S. (2011) · Biomedical Chromatography · doi:10.1002/bmc.1690 · Cited by 22
Statins Impair CD1d-Mediated Antigen Presentation through the Inhibition of Prenylation
Khan, M. A., Gallo, R. M., Renukaradhya, G. J., Du, W., Gervay‐Hague, J., & Brutkiewicz, R. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804311 · Cited by 22
Statins and their potential targets in multiple sclerosis therapy
Stüve, O., Prod’homme, T., Slavin, A., Youssef, S., Dunn, S. E., Steinman, L., & Zamvil, S. S. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.5.613 · Cited by 22
Statins as antifungal agents
Galgóczy, L. (2011) · World Journal of Clinical Infectious Diseases · doi:10.5495/wjcid.v1.i1.4 · Cited by 21
Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR)
Zhang, Y., Zhang, X., Zeng, C., Li, B., Zhang, C., Li, W., Hou, X., & Dong, Y. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.04.019 · Cited by 20

Authors: Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F.
Affiliations: University of Milan (IT)
University of Parma (IT)
Corresponding author: Corsini, Alberto
ORCID: Corsini, Alberto
Bellosta, Stefano
Baetta, Roberta
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 1999-12
Volume: 84
Issue: 3
Pages: 413-428
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/s0163-7258(99)00045-5
OpenAlex: W2045063002
Cited by: 796
References: 186
Citations by year: 2026: 5 · 2025: 6 · 2024: 27 · 2023: 19 · 2022: 17 · 2021: 25 · 2020: 17 · 2019: 14 · 2018: 21 · 2017: 30 · 2016: 30 · 2015: 27 · 2014: 35 · 2013: 31 · 2012: 38
FWCI: 5.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: statins, pharmacokinetics, pharmacodynamics, HMG-CoA reductase inhibition, mevalonate, pleiotropy, smooth muscle cell proliferation, macrophage cholesterol accumulation, atherosclerosis, drug interactions, CYP3A4, cyclosporine, rhabdomyolysis, myositis, pravastatin, fluvastatin, simvastatin, lovastatin, atorvastatin, cerivastatin
MeSH terms: Atorvastatin, Fluvastatin, Animals, Anticholesteremic Agents, Cell Division, Cytochrome P-450 Enzyme System, Drug Interactions, Fatty Acids, Monounsaturated, Heptanoic Acids, Humans, Indoles, Mevalonic Acid, Pyridines, Pyrroles, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

New insights into the pharmacodynamic and pharmacokinetic properties of statins

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks